Systemic inflammatory response syndrome (SIRS) affects vital organs that are remote from and unrelated to the original cause of inflammation. It’s responsible for damage to vital organs, leading to organ injury, organ failure and ultimately death.
Systemic Inflammatory Response Syndrome
The human body has a fierce immunological protective mechanism primarily aimed to fight pathogens such as bacteria and viruses. However, also in response to non-infectious insults (such as trauma, irradiation damage and surgery), the immune system is activated and immune mediators are released. Even if there are no pathogens to fight, in SIRS the balance between pro-inflammatory and anti-inflammatory mediators is disturbed and is tipped towards an exaggerated immune response. As such, SIRS is a systemic inflammation caused by the overreaction of the body’s own immune system resulting in collateral damage to the patient’s own organs.
Current treatment regimens for SIRS are mainly focused on combatting symptoms. The main treatment regimens consist of fluid therapy, oxygenation and vasopressors to support the body, improve cardiac output and stabilize hemodynamics and respiration.
The exaggerated inflammation is not treated specifically, leading to long recovery times and allowing the ongoing exaggerated inflammation to cause severe and often irreversible damage to organs. Moreover, current immuno-suppressors are all accompanied by increased risks of infections.
Therefore, novel treatments are needed that provide an effective solution for patients with SIRS and to prevent severe long-term organ damage and life-threatening organ failure caused by this condition.
With millions of patients suffering from SIRS each year, there is a significant unmet medical need for fast-acting drugs that target the ongoing exaggerated immune response in order to prevent severe, long-term organ damage.
EBI’s Promising Solution
The therapeutics developed by EBI target the immune response directly and thereby present a promising and novel solution for the fast and effective treatment of SIRS. In addition to directly treating the disease, immune-modulators may also prevent SIRS in patients at risk of developing an exaggerated immune response.